Периндоприл: клиническая эффективность у всех больных с сосудистым заболеванием или высоким его риском через вазопротекцию

1. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–77.
2. Yusuf S, Pepine CJ, Garces C et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173–8.
3. The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145–53.
4. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
5. The PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
6. ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 828–40.
7. Deckers JW, Goedhart DM, Boersma E et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur H Journal 2006; 27.
8. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305–15.
9. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–76.
10. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527–45.
11. Dzau V, Bernstein K, Celermaier D et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88 (Suppl. L): 1–20.
12. Карпов ЮА. Ренин-ангиотензиновая система сосудистой стенки как мишень для терапевтических вмешательств. Кардиология. 2003; 5: 97–101.
13. Ghiadoni L, Magagna A, Versari D et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281–6.
14. Ceconi C, Francolini G, Bastianon D et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drug Ther 2007; 21: 423–9.
15. Zhuo JL, Froomes P, Casley D et al. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation 1997; 96 (1): 174–82.
16. Bots ML, Remme WJ, Luscher TF et al. ACE inhibition and endothelial function: mail findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther 2007; 21: 269–79.
17. Ceconi C, Fox K, Remme WJ et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
18. Ferrari R, Fox KM. The mode of action of perindopril. In: Perindopril: a major contribution to the prevention and treatment of cardiovascular disease. Edited by R.Ferrari & KM.Fox. Wolters Kluwer, 2008; 4–13.
19. Rodriguez-Granillo GA. Long-term effect of Perindopril on coronary atherosclerosis progression (from rhe PERindopril's Prospective Effect on Coronary a Theroslerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol 2007; 100: 159–63.
20. Rodriguez-Granillo GA, Serruys PW, Garcia-Garcia HM et al. Coronary artery remodeling is related to plaque composition. Heart 2006; 92: 388–91.
21. Remme WJ, Deckers JW, Fox KM et al. Secondary prevention of coronary disease with ACE inhibition – does blood pressure reduction with perindopril explain the benefits in EUROPA? Cardiovasc Drug Ther 2008. DOI 10.1007/s10557-008-6143-6.
22. Brugts JJ, Boersma E, Deckers JW et al. Abstract 5066: The treatment effect of perindopril is consistent in all patients with vascular disease: a combined analysis of three perindopril trials. Circulation 2008; 118: S1138.

Ю.А.Карпов